Crosslinked Polymer Network for Peptide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-specific cytolytic peptides like melittin, used for cancer therapy, face off-target toxicity issues when administered intravenously due to their nonspecific action on cell membranes, leading to complications such as hemolysis, which hampers therapeutic benefits.
Innovation Solution
A crosslinked polymer network incorporating a therapeutic peptide, utilizing a stimuli-responsive zwitterionic polymer with charge-dependent properties and disulfide bonds, is developed to secure the peptide via charge interactions and crosslinking, allowing targeted delivery and release within specific cellular environments, minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific cytolytic peptides like melittin are administered intravenously for cancer therapy, then therapeutic efficacy against cancer cells is improved, but off-target toxicity increases causing hemolysis and other adverse effects
Solution Approach 1:
The system segments the therapeutic agent into two components: a cytolytic peptide (therapeutic agent) and a stimuli-responsive polymer (delivery vehicle). The peptide is encapsulated within the polymer network, separating its therapeutic function from its harmful non-specific cytolytic activity. This segmentation allows the peptide to be delivered selectively to target cells while the polymer protects it from interacting with healthy cells during circulation.
Solution Approach 2:
The stimuli-responsive polymer acts as an intermediary between the cytolytic peptide and the target cells. The polymer network serves as a carrier that protects the peptide during circulation and mediates its controlled release at the target site through stimuli-responsive mechanisms (pH change, redox reactions, or enzyme activity). This intermediary role prevents direct interaction between the peptide and healthy cells, reducing off-target toxicity.
2Speed
If the therapeutic peptide is released immediately upon administration, then therapeutic action begins quickly, but off-target effects occur before reaching the cancer cells
Solution Approach 1:
The system performs preliminary action by pre-encapsulating the cytolytic peptide within the stimuli-responsive polymer network before administration. The polymer network is designed to remain stable during circulation and only undergoes degradation or conformational change upon encountering specific intracellular stimuli. This preliminary encapsulation prevents premature release and off-target effects while ensuring rapid release once the peptide reaches the target cells.
Solution Approach 2:
The system utilizes parameter changes in the intracellular environment (pH decrease, redox potential change, or enzyme presence) to trigger peptide release. The stimuli-responsive polymer is designed to undergo structural or chemical changes in response to these parameter variations, transforming from a stable encapsulating state to a degraded or opened state that releases the peptide. This parameter-based control ensures spatial and temporal precision in peptide delivery.
3Object-affected harmful factors
If a delivery system is designed to protect the peptide during circulation, then off-target toxicity is reduced, but system complexity increases
Solution Approach 1:
The stimuli-responsive polymer utilizes intrinsic environmental parameters (pH, redox potential, enzyme activity) that naturally differ between circulation and intracellular environments. By designing the polymer to respond to these naturally occurring parameter changes, the system achieves targeted release without requiring complex external control mechanisms, active targeting ligands, or multi-component systems. This approach reduces overall system complexity while maintaining protective function during circulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system enables targeted delivery of therapeutic peptides to cancer cells with high specificity, achieving over 90% efficacy at low concentrations while minimizing harm to healthy cells, thus reducing off-target toxicity and enhancing therapeutic outcomes.
Implementation Method 1
The network includes a stimuli responsive polymer complexed with the therapeutic peptide via charge/charge interaction
Implementation Method 2
the disulfide bonds of the network can be cleaved within the cell, for instance via glutathione
Data Source
AI summary
A delivery system is described that includes a polymer network that can incorporate a therapeutic peptide for targeted delivery to a cell, e.g., a cancer cell. The polymer network can secure the therapeutic peptide via two different mechanisms. First, a polymer of the network can interact with the therapeutic peptide via charge/charge interaction to form a complex with the peptide, thereby holding the peptide within the network. Second, the polymer network can be crosslinked, providing another level of securement for holding the therapeutic peptide within the network. The two levels of securement can be reversible, and following delivery of the network to the interior of a targeted cell reversal of the securement mechanisms can release the therapeutic peptide within the cell.